Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy

Prostate

Volumn 70, Issue 12, 2010, Pages 1333-1339

  Veltri, Robert W ^a   Isharwal, Sumit ^a   Craig Miller, M ^b   Epstein, Jonathan I ^a   Partin, Alan W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Nuclear roundness variance; Prognosis; Prostate cancer

Indexed keywords

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR ROUNDNESS VARIANCE; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME; VARIANCE;

AGED; DEATH; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS; UNITED STATES;

EID: 77956374808     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21168     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
2. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349(4):366-381.
3. Nelson WG, De Weese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21(1):3-16.
4. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171(2 Pt 2):S36-S40.
5. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361(9361): 955-964. (Pubitemid 36332115)
6. Veltri RW. Molecular biology of serum biomarkers of prostate cancer. In: Kirby RS, Partin AW, Feneley MR, Parsons JK, editors. Prostate cancer: Principles and Practice. London & New York: Taylor & Francis; 2006. pp. 269-284.
7. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: Current and future diagnostic markers. Clin Cancer Res 2004;10(12 Pt 1):3943-3953. (Pubitemid 38812467)
8. Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992;23(3):273-279.
9. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI. Deoxyribonucleic acid ploidy analysis as a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 1995;153(3 Pt 2):1015-1019.
10. Veltri RW, Partin AW, Epstein JE, Marley GM, Miller CM, Singer DS, Patton KP, Criley SR, Coffey DS. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression. J Cell Biochem 1994;19:249-258.
11. Stein GS, Montecino M, van Wijnen AJ, Stein JL, Lian JB. Nuclear structure-gene expression interrelationships: Implications for aberrant gene expression in cancer. Cancer Res 2000;60(8):2067-2076. (Pubitemid 30225160)
12. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591-1597.
13. Epstein JI, Berry SJ, Eggleston JC. Nuclear roundness factor. A predictor of progression in untreated Stage A2 prostate cancer. Cancer 1984;54(8):1666-1671.
14. Diamond DA, Berry SJ, Umbricht C, Jewett HJ, Coffey DS. Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 1982;3(4):321-332. (Pubitemid 12062284)
15. Mohler JL, Partin AW, Lohr WD, Coffey DS. Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system. J Urol 1988;139(5):1080-1084.
16. Mohler JL, Partin AW, Epstein JI, Lohr WD, Coffey DS. Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. J Urol 1988;139(5):1085-1090.
17. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, Epstein JI. Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992;70(1):161-168.
18. Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW. Long-term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate 2008;68(16):1806-1815.
19. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS. A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: A critical analysis. J Urol 1989;142(5):1254-1258.
20. Veltri RW, Miller MC, Isharwal S, Marlow C, Makarov DV, Partin AW. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Cancer Epidemiol Biomarkers Prev 2008;17(1):102-110. (Pubitemid 351196279)
21. Bjornhagen V, Lindholm J, Auer G. Analysis of nuclear DNA and morphometry, and proliferating cell nuclear antigen in primary and metastatic malignant melanoma. Scand J Plast Reconstr Surg Hand Surg 1997;31(2):109-118.
22. Borland RN, Partin AW, Epstein JI, Brendler CB. The use of nuclear morphometry in predicting recurrence of transitional cell carcinoma. J Urol 1993;149(2):272-275.
23. Carducci MA, Piantadosi S, Pound CR, Epstein JI, Simons JW, Marshall FF, Partin AW. Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 1999;53(1):44-49. (Pubitemid 29016612)
24. Eynard HG, Soria EA, Cuestas E, Rovasio RA, Eynard AR. Assessment of colorectal cancer prognosis through nuclear morphometry. J Surg Res 2009;154(2):345-348.
25. Fukuzawa S, Hashimura T, Sasaki M, Yamabe H, Yoshida O. Nuclear morphometry for improved prediction of the prognosis of human bladder carcinoma. Cancer 1995;76(10):1790-1796.
26. Gearhart JP, Partin AW, Leventhal B, Beckwith JB, Epstein JI. The use of nuclear morphometry to predict response to therapy in Wilms' tumor. Cancer 1992;69(3):804-808.
27. Hogberg T, Wang G, Risberg B, Guerrieri C, Hittson J, Boeryd B, Kg B, Simonsen E. Nuclear morphometry: A strong prognostic factor for survival after secondary surgery in advanced ovarian cancer. Int J Gynecol Cancer 1992;2(4):198-206.
28. Hoque A, Lippman SM, Boiko IV, Atkinson EN, Sneige N, Sahin A, Weber DM, Risin S, Lagios MD, Schwarting R, Colburn WJ, Dhingra K, Follen M, Kelloff GJ, Boone CW, Hittelman WN. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2001;10(3):249-259. (Pubitemid 34288537)
29. Noguchi S, Tamiya S, Nagoshi M, Suita S, Fukuda T, Tsuneyoshi M. The prognostic importance of nuclear morphometry and the MIB-1 index in rhabdomyosarcoma [corrected]. Mod Pathol 1996;9(3):253-260.
30. Setala L, Lipponen P, Kosma VM, Marin S, Eskelinen M, Syrjanen K, Alhava E. Nuclear morphometry as a predictor of disease outcome in gastric cancer. J Pathol 1997;181(1):46-50. (Pubitemid 27099773)
31. Tan PH, Goh BB, Chiang G, Bay BH. Correlation of nuclear morphometry with pathologic parameters in ductal carcinoma in situ of the breast. Mod Pathol 2001;14(10):937-941. (Pubitemid 32976779)
32. Veltri RW, Marlow C, Khan MA, Miller MC, Epstein JI, Partin AW. Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4 and 5 determined by digital image analysis. Prostate 2007;67(11):1202-1210.
33. Makarov DV, Marlow C, Epstein JI, Miller MC, Landis P, Partin AW, Carter HB, Veltri RW. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate 2008;68(2):183-189. (Pubitemid 351186230)
34. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, Epstein JI. Expectant management of prostate cancer with curative intent: an update of The Johns Hopkins Experience. J Urol 2007;178(6):2359-2364.
35. HeS, Dunn KL, Espino PS, Drobic B, Li L, Yu J, Sun JM, Chen HY, Pritchard S, Davie JR. Chromatin organization and nuclear microenvironments in cancer cells. J Cell Biochem 2008;104(6): 2004-2015.
36. Isharwal S, Miller C, Marlow C, Makarov DV, Partin AW, Veltri RW. p300 (Histone Acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 2008;68(10): 1097-1104.
37. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003;63(22):7638-7640.
38. Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, Tindall DJ. p300 modulates nuclear morphology in prostate cancer. Cancer Res 2005;65(3):708-712.
39. Kortenhorst MS, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA, Rodriguez R, Veltri RW. Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo. Mol Cancer Ther 2009; 8(4):802-808.